Veopoz (pozelimab‑bbfg) — Medical Benefit Coverage Criteria for CD55‑deficient PLE (CHAPLE)
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0128E alerts
Get alerted when Policy 2026D0128E changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical benefit coverage and prior authorization criteria for Veopoz (pozelimab‑bbfg) for members on UnitedHealthcare Commercial and Individual Exchange plans for treatment of CD55‑deficient protein‑losing enteropathy (PLE/CHAPLE). It applies to providers seeking coverage under those plans.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.